February 20, 2015 -- After two years as a private company, 3SBio, a mainland China biotech, has filed to IPO on the Hong Kong Stock Exchange. According to media reports, the company will complete a $400-$500 million initial offering in Q2. 3SBio was taken private in 2013 by its CEO, Lou Jing, and CITIC Private Equity for $370 million. Although the company remains dependent upon revenues from its two mainstay products, EPIAO and TPIAO, 3SBio has been an active dealmaker, and it now has a pipeline of 20 products in development, of which 14 are being developed as China Class I New Drugs.
Help employers find you! Check out all the jobs and post your resume.
